Therapeutics News and Research

RSS

New treatment platform delivers full-length mRNA for Duchenne muscular dystrophy

A new treatment platform developed by researchers at The University of Texas MD Anderson Cancer Center was able to deliver messenger RNA (mRNA) of the full-length DMD gene into preclinical models of Duchenne muscular dystrophy, successfully restoring the production of an important muscle protein, dystrophin, and dramatically improving muscle strength, endurance and function in vivo.

11 Jun 2026

Structure of the Argonaute maturation complex guides RNA therapeutic design

RNA therapeutics have emerged as one of the most promising new classes of medicines. Eight small interfering RNA (siRNA) drugs have already been approved worldwide for the treatment of genetic diseases, yet scientists have not fully understood one of the most fundamental steps underlying their function: how Argonaute, the core protein responsible for gene silencing, becomes activated.

11 Jun 2026

Low-methionine diet shows promise against aggressive brain tumors

An unexpected lab observation led a team of scientists to discover how diet can influence survival in animal models of glioma, one of the most aggressive and deadly forms of brain cancer.

10 Jun 2026

New DNA tetrahedron nanostructures improve targeted cancer therapy delivery

Conventional cancer treatments, such as chemotherapy, often lack specificity and can damage both cancerous and healthy cells, leading to severe side effects.

10 Jun 2026

Laverock Therapeutics reports key oncology research milestones

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programs for solid tumor indications.

From Laverock Therapeutics 10 Jun 2026

Study identifies key protein driving colon cancer drug resistance

One of the most widely used chemotherapeutic agents for colorectal cancer is 5-fluorouracil (5-FU), a cornerstone treatment that has improved outcomes for countless patients.

9 Jun 2026

Realistic cellular conditions revive previously dismissed drug candidates

A drug once dismissed as ineffective suddenly worked - when scientists tested it under more realistic conditions that mimic the human body.

9 Jun 2026

Advanced MRI scans predict chronic kidney disease in patients undergoing nephrectomy

An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for innovative imaging research that may help physicians identify patients at increased risk of chronic kidney disease (CKD) before they undergo surgery for kidney tumors.

9 Jun 2026

Experimental two‑in‑one vaccine shows success in human LASSARAB trial

Researchers from Thomas Jefferson University and the University of Maryland School of Medicine have reported encouraging results from the first human clinical trial of LASSARAB, an experimental vaccine designed to protect against Lassa fever and rabies in a single formulation.

9 Jun 2026

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Professor Heddle's insights on nanobiology and AI highlight their potential to innovate drug delivery and vaccine development, addressing critical health needs.

9 Jun 2026

Sugar-sweetened beverage taxes gain momentum across the globe

One of the challenges public health officials face in reducing diet-related disease is the relatively easy and inexpensive access to sugar-sweetened beverages globally.

9 Jun 2026

Oral GLP-1 RA reduces blood glucose and bodyweight among people with type 2 diabetes

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight.

8 Jun 2026

Online tool transforms patient experience in national cancer trials

In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal (PEP).

8 Jun 2026